• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
The first FDA-approved Alzheimer’s blood test — and the power of real-world data to measure its impact

The first FDA-approved Alzheimer’s blood test — and the power of real-world data to measure its impact

by Truveta staff | Jun 19, 2025 | Data

In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease, making early detection more accessible than ever. The Lumipulse test measures biomarkers in the blood associated with Alzheimer’s pathology, offering a simpler alternative to...

Share this


Recent posts

  • The first FDA-approved Alzheimer’s blood test — and the power of real-world data to measure its impact
  • New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization
  • Understanding the impact of the COVID-19 pandemic on childhood MMR vaccination patterns

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice